Bad Miss For Biocon’s Bevacizumab In US But Firm In 'Good Place'
Bicara To Raise Funds In The Coming Fiscal Year
Biocon awaits site inspection after pandemic-amplified delays keep its Viatris-partnered bevacizumab out of the US market, though the Indian company believes they can still make good and garner market share. All eyes are also on traction for their insulin glargine via increased share of formulary contracts.
